• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Publication

Article

March 30, 2019

Pharmacy Practice in Focus: Health Systems

March 2019
Volume8
Issue 2

News and Trends March 2019

FDA Approves Subcutaneous Herceptin Combo Therapy for Patients With Breast Cancer

by Jennifer Barrett

FDA officials have approved trastuzumab (Herceptin) subcutaneous (SC) injection for certain patients with HER2-positive early and metastatic breast cancer, according to a statement. The approval is based on data from 3 clinical trials in HER2-positive early breast cancer: HannaH, SafeHER, and PrefHER.

The trastuzumab and hyaluronidase-oysk combination is indicated for patients with early disease in combination with chemotherapy, for metastatic disease in combination with paclitaxel, or alone in patients who have received 1 or more chemotherapy regimens.

This SC treatment includes the same monoclonal antibody as intravenous (IV) trastuzumab in combination with recombinant human hyaluronidase PH20, an enzyme that helps deliver trastuzumab under the skin, according to Genentech.

It is a ready-to-use formulation that can be administered in 2 to 5 minutes.

In the HannaH study, neoadjuvant and adjuvant SC trastuzumab and hyaluronidase-oysk treatments were compared with IV trastuzumab, both in combination with chemotherapy. Patients administered SC trastuzumab and hyaluronidase-oysk demonstrated noninferior levels of trastuzumab in the blood and noninferior clinical

efficacy compared with IV trastuzumab.

The SafeHER study evaluated adjuvant trastuzumab and hyaluronidase-oysk and found no new safety signals, according to the data.

Reference

1. FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers [news release]. South San Francisco, California; February 28, 2019: Genentech. gene.com/media/press-releases/14779/2019-02-28/fda-approves-herceptin-hylecta-for-subcu. Accessed February 28, 2019.

FDA Accepts sNDA for AML Therapy

by Jennifer Nessel

The fda has accepted a supplemental new drug application (sNDA) for ivosidenib (Tibsovo, Agios Pharmaceuticals) for patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation who are not eligible for standard therapy.1 Ivosidenib is a firstin-class, oral, targeted inhibitor of mutant IDH1.

The FDA accepted the ivosidenib sNDA under its Real-Time Oncology Review pilot program, whose goal is to streamline reviews for oncology drugs by allowing the agency access to clinical trial data before a formal submission, according to a statement.

The submission was based on results from patients with untreated AML from the phase 1 dose-escalation and expansion study of ivosidenib in patients with newly diagnosed AML who were ineligible for standard treatment, according to a statement.1

The sNDA was granted priority review and has been given a Prescription Drug User Fee Act action date of June 21, 2019.

References

  • American Cancer Society. What is acute myeloid leukemia (AML)? cancer.org/cancer/acute-myeloid-leukemia/about/what-is-aml.html. Updated August 21, 2018. Accessed February 21, 2019.
  • Agios announces FDA acceptance of supplemental new drug application for TIBSOVO® (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation not eligible for standard therapy [news release]. Cambridge, Massachusetts;February 20, 2019: GlobeNewswire. globenewswire.com/news-release/2019/02/20/1738209/0/en/Agios-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-TIBSOVO-ivosidenib-for-the-Treatment-of-Patients-with-Newly-Diagnosed-Acute-Myeloid-Leukemia-with-an-IDH1-Mu.html. Accessed February 21, 2019.

Generic Therapies for Opioid Dependence Hit the Market

by Kristen Coppock

Two generic buprenorphine and naloxone sublingual film products are on the market to treat opioid dependence, following FDA approval and patent litigation.

The therapies, from Mylan and Dr. Reddy’s Laboratories, are generic equivalents of Indivior PLC’s Suboxone sublingual film.1,2 FDA officials approved both generic versions of buprenorphine and naloxone sublingual film in June 2018. They were the first generic versions of Indivior’s product, according to the agency.3

“When coupled with other social, medical, and psychological services, medication-assisted treatments are often the most effective approach for opioid dependence,” FDA Commissioner Scott Gottlieb, MD, said in a statement.3

“Patients addicted to opioids who are eventually treated for that addiction and successfully transition onto medicines like buprenorphine aren’t swapping one addiction for another, as is sometimes unfortunately said,” Gottlieb said. “They’re able to regain control of their lives and end all the destructive outcomes that come with being addicted to opioids.”

Dr. Reddy’s Laboratories’ buprenorphine and naloxone sublingual film product, in doses of 2.0 mg/0.5 mg, 4.0 mg/1.0 mg, 8.0 mg/2.0 mg, and 12.0 mg/3.0 mg, launched following its FDA approval. However, sales and commercialization activities were halted because of a legal challenge related to Indivior’s patent.

According to Dr. Reddy’s Laboratories, its generic product resumed shipping in late February, following a decision in the company’s favor by the US Court of Appeals for the Federal Circuit.1

“We are pleased with the decision of the appellate court in Dr. Reddy’s favor, vacating the preliminary injunction that had prevented Dr. Reddy’s from continuing to market this important drug to the public,” Marc Kikuchi, CEO of North America Generics, said in a statement.1 “Dr. Reddy’s is committed to providing affordable treatment options for opioid use disorder and

addiction. We look forward to helping patients and our communities in the United States who are impacted by

the opioid epidemic.”

Mylan also said it is launching its buprenorphine and naloxone sublingual film product in doses of 8 mg/2 mg and 12 mg/3 mg, following final FDA approval for the treatment’s abbreviated new drug application.

References

  • Dr. Reddy's Laboratories announces the re-launch of its buprenorphine and naloxone Sublingual Film after favorable ruling in patent litigation [news release]. Hyderabad, India, and Princeton, New Jersey; February 20, 2019; Dr. Reddy's Laboratories. businesswire.com/news/home/20190220005717/en/Dr.-Reddys-Laboratories-Announces-Re-Launch-Buprenorphine-Naloxone. Accessed February 22, 2019.
  • Mylan launches generic Suboxone Sublingual Film to treat opioid dependence [news release]. Hertfortshire, England, and Pittsburgh, Pennsylvania; February 22, 2019: Mylan. investor.mylan.com/news-releases/news-release-details/mylan-launches-generic-suboxoner-sublingual-film-treat-opioid. Accessed February 22, 2019.
  • FDA approves first generic versions of Suboxone Sublingual film, which may increase access to treatment for opioid dependence [news release]. Silver Spring, MD: June 14, 2018; FDA website. www.fda.gov/newsevents/newsroom/pressannouncements/ucm610807.htm. Accessed February 22, 2018.

Visit us at pharmacytimes.com to read more related articles.

Articles in this issue

Use AUC to Optimize Vancomycin Dosing
Use AUC to Optimize Vancomycin Dosing
Approach Respiratory Illnesses Rationally
Approach Respiratory Illnesses Rationally
Manage Acute Pain in Those Using Opioids
Manage Acute Pain in Those Using Opioids
Documenting 340B Value Is Key to Success
Documenting 340B Value Is Key to Success
Panelists Discuss Challenges of Diagnosing HE
Panelists Discuss Challenges of Diagnosing HE
News and Trends March 2019
Perform an AOR to Comply With USP
Perform an AOR to Comply With USP
Enterprise Collaborations Help Meet Challenges
Enterprise Collaborations Help Meet Challenges
Cancer Pain Treatment Remains a Challenge
Cancer Pain Treatment Remains a Challenge
Here Is What to Know About Vaccines for Seniors
Here Is What to Know About Vaccines for Seniors
RA Treatment Strategies Can Keep the Pain at Bay
RA Treatment Strategies Can Keep the Pain at Bay
The Health-System Pharmacist Role in Optimizing Outcomes for Patients Who Need DOAC Reversal Agents
Drug Price Increases: Here We Go Again?
Drug Price Increases: Here We Go Again?
Helping Patients Breathe Easier
Helping Patients Breathe Easier
Improving the Performance of Specialty Pharmacists in the Care of Patients With Pulmonary Arterial Hypertension
Related Videos
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Advertisement
Olaparib box | Image Credit: © luchschenF - stock.adobe.com
May 15th 2025

Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Intestinal carcinoma, colorectal cancer, bowel neoplasia, 3D illustration
May 15th 2025

High LDL Cholesterol Associated With Earlier Progression in Synchronous Metastatic Colorectal Cancer

Luke Halpern, Assistant Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
Vitamin A supplements -- Image credit: 1989STUDIO | stock.adobe.com
May 15th 2025

Evidence Over Anecdotes: The Misuse of Vitamin A During Measles Outbreaks

Curtis E. Haas, PharmD, FCCP
CAR T-cell visualization | Image Credit: © Wimon - stock.adobe.com
May 14th 2025

Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Olaparib box | Image Credit: © luchschenF - stock.adobe.com
May 15th 2025

Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Intestinal carcinoma, colorectal cancer, bowel neoplasia, 3D illustration
May 15th 2025

High LDL Cholesterol Associated With Earlier Progression in Synchronous Metastatic Colorectal Cancer

Luke Halpern, Assistant Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
Vitamin A supplements -- Image credit: 1989STUDIO | stock.adobe.com
May 15th 2025

Evidence Over Anecdotes: The Misuse of Vitamin A During Measles Outbreaks

Curtis E. Haas, PharmD, FCCP
CAR T-cell visualization | Image Credit: © Wimon - stock.adobe.com
May 14th 2025

Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.